Discordant American College of Physicians and international rheumatology guidelines for gout management: consensus statement of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN)
暂无分享,去创建一个
R. Terkeltaub | Hyon K. Choi | K. Saag | M. Doherty | N. Dalbeth | L. Stamp | A. So | P. Richette | F. Lioté | T. Bardin
[1] L. Duley,et al. OP0268 Nurse-led care versus general practitioner care of people with gout: a uk community-based randomised controlled trial , 2017 .
[2] Hyon K. Choi,et al. Trends in Gout and Rheumatoid Arthritis Hospitalizations in Canada From 2000 to 2011 , 2017, Arthritis care & research.
[3] R. McLean. The Long and Winding Road to Clinical Guidelines on the Diagnosis and Management of Gout , 2017, Annals of Internal Medicine.
[4] T. Mikuls,et al. To Treat or Not to Treat (to Target) in Gout , 2017, Annals of Internal Medicine.
[5] P. Shekelle,et al. Management of Gout: A Systematic Review in Support of an American College of Physicians Clinical Practice Guideline , 2017 .
[6] A. Qaseem,et al. Management of Acute and Recurrent Gout: A Clinical Practice Guideline From the American College of Physicians. , 2017, Annals of internal medicine.
[7] J. Singh,et al. Chasing crystals out of the body: will treat to serum urate target for gout help us get there? , 2016, Annals of the rheumatic diseases.
[8] Hyon K. Choi,et al. Editorial: Do Not Let Gout Apathy Lead to Gouty Arthropathy , 2016, Arthritis & rheumatology.
[9] M. Weisman,et al. Treat-to-target (T2T) recommendations for gout , 2016, Annals of the rheumatic diseases.
[10] F. Becce,et al. 2016 updated EULAR evidence-based recommendations for the management of gout , 2014, Annals of the rheumatic diseases.
[11] Hyon K. Choi,et al. Trends in Gout and Rheumatoid Arthritis Hospitalizations in the United States, 1993-2011. , 2016, JAMA.
[12] R. Terkeltaub,et al. THU0537 Clinical Response of Tophus and Flares To Extended Use of Lesinurad in Combination with A Xanthine Oxidase Inhibitor in Patients with Gout , 2016 .
[13] K. Saag,et al. THU0495 Examination of Serum Uric Acid (Sua) Lowering and Safety with Extended Treatment with Lesinurad and Allopurinol in Subjects with Gout , 2016 .
[14] M. Doherty,et al. Comorbidities in patients with gout prior to and following diagnosis: case-control study , 2014, Annals of the rheumatic diseases.
[15] N. Dalbeth,et al. Factors influencing the crystallization of monosodium urate: a systematic literature review , 2015, BMC Musculoskeletal Disorders.
[16] J. Singh,et al. Erratum to: Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort , 2015, Arthritis Research & Therapy.
[17] 陳建勳,et al. Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study , 2015 .
[18] W. Taylor,et al. An Observational Study of Gout Prevalence and Quality of Care in a National Australian General Practice Population , 2015, The Journal of Rheumatology.
[19] Hyon K. Choi,et al. Flare frequency, healthcare resource utilisation and costs among patients with gout in a managed care setting: a retrospective medical claims-based analysis , 2015, BMJ Open.
[20] P. Clerson,et al. Revisiting comorbidities in gout: a cluster analysis , 2013, Annals of the Rheumatic Diseases.
[21] Hyon K. Choi,et al. Cost-Effectiveness of Allopurinol and Febuxostat for the Management of Gout , 2014, Annals of Internal Medicine.
[22] W. Taylor,et al. Toward Development of a Tophus Impact Questionnaire: A Qualitative Study Exploring the Experience of People With Tophaceous Gout , 2014, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.
[23] J. Singh. The impact of gout on patient’s lives: a study of African-American and Caucasian men and women with gout , 2014, Arthritis Research & Therapy.
[24] N. Dalbeth,et al. Exploratory Study of Radiographic Change in Patients With Tophaceous Gout Treated With Intensive Urate‐Lowering Therapy , 2014, Arthritis care & research.
[25] C. Bombardier,et al. Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative , 2013, Annals of the rheumatic diseases.
[26] Mei‐Ling Yeh. Achieving knowledge translation in nursing care: the need for greater rigor in applying evidence to practice. , 2014, The journal of nursing research : JNR.
[27] F. Ottery,et al. Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy , 2013, Arthritis Research & Therapy.
[28] Hyon K. Choi,et al. Managing gout needs more than drugs: ‘Il faut le savoir-faire, l'Art et la manière’ , 2013, Annals of the rheumatic diseases.
[29] Michael Pignone,et al. How to decide whether a clinical practice guideline is trustworthy. , 2013, JAMA.
[30] F. Ottery,et al. Long-term safety of pegloticase in chronic gout refractory to conventional treatment , 2012, Annals of the rheumatic diseases.
[31] M. Doherty,et al. Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study , 2012, Annals of the rheumatic diseases.
[32] D. Khanna. American College of Rheumatology guidelines for management of gout , 2013 .
[33] R. Terkeltaub,et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis , 2012, Arthritis care & research.
[34] Charles King,et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia , 2012, Arthritis care & research.
[35] D. Khanna,et al. Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: Results from a cross-sectional survey , 2012, Health and Quality of Life Outcomes.
[36] W. Taylor,et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. , 2012, Arthritis and rheumatism.
[37] J. Singh,et al. Improved Health-related Quality of Life and Physical Function in Patients with Refractory Chronic Gout Following Treatment with Pegloticase: Evidence from Phase III Randomized Controlled Trials , 2012, The Journal of Rheumatology.
[38] K. Rascati,et al. Evaluation of health care costs and utilization patterns for patients with gout. , 2012, Clinical therapeutics.
[39] W. White,et al. Pegloticase and Chronic Gout—Reply , 2011 .
[40] P. Lipsky,et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. , 2011, JAMA.
[41] P. Shekelle,et al. The Development of Clinical Practice Guidelines and Guidance Statements of the American College of Physicians: Summary of Methods , 2010, Annals of Internal Medicine.
[42] Jillian Cornish,et al. Cellular characterization of the gouty tophus: a quantitative analysis. , 2010, Arthritis and rheumatism.
[43] H. Schumacher,et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial , 2010, Arthritis research & therapy.
[44] M. Fuldeore,et al. Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis* , 2009, Current medical research and opinion.
[45] H. Schumacher,et al. Clinical Efficacy and Safety of Successful Longterm Urate Lowering with Febuxostat or Allopurinol in Subjects with Gout , 2009, The Journal of Rheumatology.
[46] S. Nicolaou,et al. Dual energy computed tomography in tophaceous gout , 2008, Annals of the rheumatic diseases.
[47] H. Schumacher,et al. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. , 2008, Rheumatology.
[48] G. Gamble,et al. Mechanisms of bone erosion in gout: a quantitative analysis using plain radiography and computed tomography , 2008, Annals of the rheumatic diseases.
[49] H. Schumacher,et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. , 2008, Arthritis and rheumatism.
[50] J. Avorn,et al. Uric acid lowering therapy: prescribing patterns in a large cohort of older adults , 2007, Annals of the rheumatic diseases.
[51] F. Perez-Ruiz,et al. Ultrasonographic measurement of tophi as an outcome measure for chronic gout. , 2007, The Journal of rheumatology.
[52] E. Pascual,et al. Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout , 2007, Annals of the rheumatic diseases.
[53] J. Stockman,et al. Febuxostat Compared with Allopurinol in Patients With Hyperuricemia and Gout , 2007 .
[54] B. Thiers. HLA-B*5801 Allele as a Genetic Marker for Severe Cutaneous Adverse Reactions Caused by Allopurinol , 2006 .
[55] F. Perez-Ruiz,et al. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. , 2002, Arthritis and rheumatism.
[56] H. Schumacher,et al. Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? , 2001, The Journal of rheumatology.
[57] J. Pijoan,et al. Improvement of Renal Function in Patients with Chronic Gout after Proper Control of Hyperuricemia and Gouty Bouts , 2000, Nephron.
[58] D. Sackett,et al. Evidence based medicine: what it is and what it isn't , 1996, BMJ.
[59] W. Downie,et al. Observations on spontaneous improvement in patients with podagra: implications for therapeutic trials of non-steroidal anti-inflammatory drugs. , 1987, British journal of clinical pharmacology.
[60] R Turner,et al. REAL-TIME CARDIAC IMAGING OF ADULTS AT VIDEO FRAME RATES BY MAGNETIC RESONANCE IMAGING , 1986, The Lancet.
[61] G. H. Nancollas,et al. The crystallization and dissolution of sodium urate , 1981 .
[62] H. Schumacher. Pathology of the synovial membrane in gout , 1975 .
[63] H. Schumacher. Pathology of the synovial membrane in gout. Light and electron microscopic studies. Interpretation of crystals in electron micrographs. , 1975, Arthritis and rheumatism.
[64] A. Gutman. The past four decades of progress in the knowledge of gout, with an assessment of the present status. , 1973, Arthritis and rheumatism.
[65] J. Loeb. The influence of temperature on the solubility of monosodium urate. , 1972, Arthritis and rheumatism.
[66] D. Mccarty. A historical note: Leeuwenhoek's description of crystals from a gouty tophus. , 1970, Arthritis and rheumatism.
[67] J. Seegmiller. The acute attack of gouty arthritis. , 1965, Arthritis and rheumatism.
[68] D. Mccarty,et al. ACUTE ARTHRITIS IN MAN AND DOG AFTER INTRASYNOVIAL INJECTION OF SODIUM URATE CRYSTALS , 1962 .
[69] D. Mccarty,et al. Identification of urate crystals in gouty synovial fluid. , 1961, Annals of internal medicine.
[70] P. Hench. DIAGNOSIS AND TREATMENT OF GOUT AND GOUTY ARTHRITIS , 1941 .